SEC Form 4 · accession 0001628280-26-056285
Amneal Pharmaceuticals, Inc. · AMRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chirag K. Patel
Officer — President & Co-CEO · Director
Period of report
Aug 10, 2026
Accepted (ET)
Aug 12, 2026 · 4:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001723128
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Aug 10, 2026 | A | 6,381,734 | — | A | 6,381,734 | I | By Limited Liability Companies |
| Class A Common Stock | holding | — | — | — | 1,393,470 | D | ||
| Class A Common Stock | holding | — | — | — | 21,269,420 | I | By Family Trusts |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.